COVID-19, the USA and the drug of Cuba: Itolizumab adopted in the United States, Mexico, and Brazil
COVID-19, Itolizumab, a monoclonal antibody developed by the Center for Molecular Immunology (CIM), in collaboration with the Indian company Biocon, has received authorization to begin phase III clinical trials in coronavirus patients in…